Nachrichten zur Cytokinetics Inc. Aktie

Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet

The mean of analysts price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly…

Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?

CYTK has gained 18.4% YTD as Myqorzos FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.…

GNW-News: Cytokinetics bringt MYQORZO® (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland

^Auf den erfolgreichen Start in den USA folgt nun die Markteinführung in Europa SOUTH SAN …

Cytokinetics: Biopharma-Spezialist für Herzmuskeltherapien treibt Myqorzo-Expansion voran!

Mit einem starken US-Marktstart von Myqorzo wandelt sich Cytokinetics zu einem kommerziellen Biotechunternehmen. Der erfolgreiche US-Marktstart von Myqorzo und…

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million

SOUTH SAN FRANCISCO, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing…

Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -1.63% and +356.43%, respectively, for the quarter ended December 2025. Do the…

Cytokinetics (CYTK) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DateTuesday, February 24, 2026 at 4:30 p.m. ETCall participantsPresident and Chief Executive Officer — Robert I.…

Cytokinetics: Small Label Differences With Big Commercial Stakes

…

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

…

Cytokinetics gains FDA approval of aficamten for hypertrophic cardiomyopathy

…

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

B. Lynne Parshall sold $323,650 worth of Cytokinetics shares in November.…

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Key PointsAdded 458,295 shares of Cytokinetics, a $25,187,893 net position changeTransaction represents a 13.8% position relative to 13F reportable assets…

Cytokinetics: Approval Catalyst In December - But Risk Reward Is Not Compelling

…

CYTK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action – CYTK

NEW YORK, Nov. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?

Cytokinetics shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.…

Cytokinetics (CYTK) director Kaye sells $336,789 in stock By Investing.com

Cytokinetics (CYTK) director Kaye sells $336,789 in stock…

Cytokinetics Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK

NEW YORK and NEW ORLEANS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and…

Cytokinetics stock hits 52-week high at 64.33 USD By Investing.com

Cytokinetics stock hits 52-week high at 64.33 USD…

CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm

CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm…

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Shares of Cytokinetics, which targets medicines for specialty heart diseases, have jumped about 69% over the past three months and…

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Robert Blum, Cytokinetics CEO, joins Power Lunch to discuss the companys value proposition, what the company is working towards and…

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cytokinetics, Incorporate of Class Action Lawsuit and Upcoming Deadlines – CYTK

NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

ROSEN, A LEADING LAW FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ROSEN, A LEADING AND RANKED FIRM, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK

NEW YORK, Oct. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI to Contact the Firm About their Rights in Filed Class Action Lawsuits

NEW YORK, Oct. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Pivotal-Point Nachverfolgung Cytokinetics: Fortschritte bei Zulassungen und eine starke Pipeline sind Türöffner für den Milliardenmarkt Herzkrankheiten!

Das auf Muskelbiologie spezialisierte Biopharma-Unternehmen konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung von Medikamenten zur Behandlung von Krankheiten mit…

Cytokinetics: H.C. Wainwright sieht 121 % Kurspotenzial nach der Präsentation der primären Ergebnisse der Phase-3-Studie MAPLE-HCM

Cytokinetics (CYTK) ist ein Spezialist für kardiovaskuläre Biopharmazeutika und der Konzern konnte jüngst mit wichtigen Entwicklungen aufwarten, die sich hauptsächlich…

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds securities class…

Bragar Eagel & Squire, P.C. Reminds Investors of VFC, Cytokinetics, Quanex, and RCI that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

dpa-AFX ProFeed